Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
A multicenter trial was conducted in 267 centers in Italy to evaluate the efficacy, acceptability and safety of a monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 150 micrograms desogestrel (Marvelon) 13,290 women were followed up for a total of 74,967 cycles. No pregnancies due to method failure were reported and only three because of patient failure. Cycle control was good. There was a decrease in the occurrence of irregular cycles and in the duration and amount of menstrual bleeding; the incidence of breakthrough bleeding and spotting was low. No severe side-effects occurred and the incidence of minor complaints was generally lower during treatment than in the pre-treatment cycle. Body weight and blood pressure were not significantly altered.
Bilotta
P
P
Medical Department, Dott. R. Ravasini & Cia. S.p.A., Rome, Italy.
Favilli
S
S
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003277:Contraceptives, Oral, Combined; D017135:Desogestrel; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D009652:Norpregnenes / Q000009:adverse effects / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000009:adverse effects / Q000494:pharmacology*
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D017135:Desogestrel